New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
07:23 EDTCANFCan-Fite BioPharma says CF602 demonstrates efficacy in preclinical studies
Subscribe for More Information
January 22, 2015
08:54 EDTCEMIChembio Diagnostics to acquire rights to Sure Check HIV assay in June 2016
Subscribe for More Information
January 15, 2015
06:10 EDTAMBSAmarantus Bioscience's LymPro test confirms biomarkers for Alzheimer's
Amarantus BioScience reported positive top-line results of its LP-002 study of the Lymphocyte Proliferation Test blood diagnostic for Alzheimer's disease. Results from the 140-subject study demonstrated that multiple individual biomarkers achieved statistically significant results to correctly identify patients with AD from healthy controls. Biomarker services using LymPro Test biomarker data are now available to the pharmaceutical industry for Investigational Use Only. In addition, the company identified a new, undisclosed biomarker that correlates with AD diagnosis and could become a central component of a multivariate algorithm currently being analyzed by company scientists to deliver a simplified assessment of an individual's likelihood of having Alzheimer's disease. Each of the three stages of Alzheimer's disease showed significant differences in marker expression as compared to healthy controls. In addition, after further analysis of a 44 subject 7-year longitudinal retrospective study, LymPro was able to distinguish Alzheimer's disease from Parkinson's and vascular dementias with a sensitivity of 94% and specificity of 65%.
January 14, 2015
07:07 EDTNURONeuroMetrix reports 'strong' interest in Quell wearable pain relief technology
Subscribe for More Information
January 13, 2015
17:36 EDTAGENQVT Financial reports 9.82% passive stake in Agenus

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use